CRM
Manages customer relationships.
Investor overview / private01 / Company Genome AI
A new management layer
after CRM, ERP, BI and AI.
Company Genome AI is an intelligent system for managing an organisation. It preserves organisational memory, understands decision logic and helps keep the organisation on course in a changing world.
02 / The Problem
Technology automates tasks. Yet organisations still lose their own operating logic.
ERP
Manages processes and resources.
BI
Collects and interprets data.
AI
Works with knowledge and discrete tasks.
Company Genome AI
Connects the organisation’s memory, principles, strategy and decisions.
03 / Product Ladder
From corporate memory to functional autonomy.
AI Guardian
Turns history, documents and experience into accessible corporate memory.
AI Ideologist
Recommends decisions based on the nature and principles of a specific company.
AI Coordinator
Assigns tasks, provides recommendations and supports execution.
Autonomous Function Management
Coordinates several functions and makes decisions within defined boundaries.
04 / System Foundation
An AI assistant is not valuable in isolation. Its value comes from the company context.
Founder’s White Book
Captures the founder’s intent, principles, boundaries and decision criteria.
Corporate Constitution
Defines a shared mission, values, decision rules and acceptable organisational scenarios.
Digital Modules
Embed this logic across sales, marketing, HR, finance, procurement and other functions.
05 / Why Now
Companies already have access to AI. The next question is what intelligence they are scaling.
Without corporate memory, language and principles, artificial intelligence reproduces fragments. Company Genome AI provides the foundation for aligned decisions and management continuity.
06 / Path to Platform
From project methodology to a repeatable system.
01
Formalising the company’s management logic.
02
Creating corporate memory and a normative core.
03
Deploying AI assistants for leaders and their teams.
04
Scaling functional modules across the organisation.
07 / Strategic Partner
We are looking for more than capital. We are looking for a partner to build a new category.
We value entrepreneurial and leadership experience, the ability to scale a company, access to capital, reputation and readiness to participate in the project’s long-term architecture.
Joint Governance
The founder retains final decision rights on mission, values and methodology. Budget, annual strategy, new markets, investments and major transactions are joint decisions.
Staged Tranches
Tranches convert into equity when agreed milestones are achieved. Possible structures include a fixed equity stake, conversion at valuation or a valuation cap; the reference model is RUB 30 million for 30%.
Turning the Idea into an Organisation
Building a core team in Dubai, Abu Dhabi or Moscow; PR and market development; strengthening IT infrastructure; and further legal protection.
Institutionalisation and Value Participation
The long-term objective is an independent school of practice, a proprietary modelling language, institutional reputation and reduced dependence on the founder. Profit distribution: 50/50 until the strategic partner’s funds are repaid, then pro rata to ownership.
The investment is venture in nature. The final structure, equity participation, milestones and legal model are agreed by the parties during negotiations and documented formally.
08 / Investment Opportunity
Market Formation, Sales Cycle, Founder Dependency
A new market is developed through PR and education; a long sales cycle through systematic market development; founder dependency through formalising the organisation’s logic; and copying risk through know-how protection and reputation.
Fair Market Value
An exit begins with an independent valuation of the company. The founder has the first right to buy the stake, followed by the strategic partner; a sale to a third party is possible while preserving the company’s corporate identity.
We are building the category of organisational intelligence.
We are looking for partners to turn the accumulated methodology and product architecture into a scalable Company Genome AI system.